A dengue vaccine candidate had 62.0% efficacy against the illness and 83.6% efficacy against hospitalized dengue in children and adolescents, according to recently reported trial results. The data comes from an ongoing phase 3 study of Takeda Pharmaceutical’s TAK-003 candidate vaccine, which showed continued protection against dengue illness and hospitalization, regardless of previous dengue exposure, with no important safety risks identified through 3 years after vaccination, according to the company. The vaccine showed greater overall efficacy among seropositive children and adolescents (65.0%) than among their seronegative counterparts (54.3%). The trial enrolled more than 20,000 healthy individuals 4 to 16 years old in dengue-endemic countries in Latin America and Asia. The safety and efficacy results were presented at the 2021 Conference of the International Society of Travel Medicine on May 22.
Improving the health of children worldwide through philanthropic support of scientific and educational programs.
